Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67

Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47

Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med (2013) 13.92

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24

Doxorubicin-induced cardiomyopathy. N Engl J Med (1998) 9.08

Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 4.57

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (1984) 4.52

Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol (1994) 4.50

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19

Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol (2013) 4.03

Trastuzumab in the treatment of breast cancer. N Engl J Med (2005) 3.86

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation (2006) 3.71

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62

Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20

ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation (2003) 2.97

Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med (2009) 2.89

Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res (2004) 2.77

Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol (2006) 2.52

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer (2010) 2.25

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol (2010) 2.18

Trastuzumab-associated cardiotoxicity. Cancer (2002) 2.06

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol (2010) 1.98

NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res (2007) 1.83

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol (2009) 1.80

Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol (1987) 1.71

Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol Cell Biol (2006) 1.70

Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation (2013) 1.67

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med (1987) 1.60

Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol (1996) 1.57

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol (1999) 1.47

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol (2008) 1.44

Clinical cardiac tolerability of trastuzumab. J Clin Oncol (2004) 1.43

Herceptin and the heart--a molecular modifier of cardiac failure. N Engl J Med (2006) 1.33

Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta (1992) 1.29

Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J (1997) 1.27

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.16

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol (1998) 1.15

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol (2011) 1.10

Cardiotoxicity profile of trastuzumab. Drug Saf (2008) 1.09

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology (2008) 1.07

A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer (1991) 1.02

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol (1988) 0.98

Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer (1990) 0.97

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol (2014) 0.96

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res (1996) 0.95

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol (2012) 0.94

Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther (2009) 0.90

Anthracyclines and heart failure. N Engl J Med (2013) 0.89

Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs (2007) 0.87

A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol (1986) 0.84

Trastuzumab in the management of early and advanced stage breast cancer. Biologics (2007) 0.84

Cardio-oncology/onco-cardiology. Clin Cardiol (2010) 0.84

The cardiovascular perils of cancer survivorship. N Engl J Med (2013) 0.81

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev (2006) 0.80

The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol (2015) 0.77

Chemotherapy-induced cardiotoxicity in women. Heart Fail Clin (2011) 0.76

Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic. Ochsner J (2016) 0.75

From the Editor's Desk: Ochsner Journal Focus Issue: Cardiovascular Diseases. Ochsner J (2016) 0.75